• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Cost-cutting impacts Positron results

Article

PET developer Positron’s year of hibernation was reflected in the company’s 1998 financial results (end-December), which were released this month. The Houston company sold no systems in 1998, compared with one sale of $1.1 million the year

PET developer Positron’s year of hibernation was reflected in the company’s 1998 financial results (end-December), which were released this month. The Houston company sold no systems in 1998, compared with one sale of $1.1 million the year before. The vendor reported revenues of $2 million last year, thanks to service and fee-per-scan revenues, while in 1997 Positron had sales of $3.5 million. Positron did have some good news for the year, however. Thanks to cost-cutting efforts, its net loss decreased to $724,000, an improvement on last year’s loss of $4.5 million.

Yet despite modest results for 1998, Positron may be gaining strength. In April 1998, the company was unsure it could continue as a going concern; in May, it signed an agreement with South San Francisco CT developer Imatron, in which Imatron acquired a majority stake in Positron and began feeding the company working capital (SCAN 5/13/98). Imatron’s purchase was finalized early this year, and since then Imatron has been negotiating with third-party investors to help resuscitate the company (SCAN 2/3/99).

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.